Cite
HARVARD Citation
Butzkueven, H. et al. (2020). Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ open. 10 (10), p. . [Online].